Cargando…

Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma

Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zhongben, Lin, Feng, Xiao, Jiarong, Du, Xiaojun, Zhang, Jian, Li, Sini, Tang, Gongshun, Chen, Chen, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012760/
https://www.ncbi.nlm.nih.gov/pubmed/33816237
http://dx.doi.org/10.3389/fonc.2021.605658
_version_ 1783673434083950592
author Tang, Zhongben
Lin, Feng
Xiao, Jiarong
Du, Xiaojun
Zhang, Jian
Li, Sini
Tang, Gongshun
Chen, Chen
Li, Jian
author_facet Tang, Zhongben
Lin, Feng
Xiao, Jiarong
Du, Xiaojun
Zhang, Jian
Li, Sini
Tang, Gongshun
Chen, Chen
Li, Jian
author_sort Tang, Zhongben
collection PubMed
description Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiotherapy and patients benefit less from chemotherapy, but few studies have focused on targeted therapy, and their conclusions are inconsistent. With respect to primary pulmonary adenoid cystic carcinoma, large-scale studies cannot be conducted due to its low incidence, and studies on the targeted therapy of it are very scarce. A few case reports indicate that targeted therapy can be effective however, suggesting that it may be a good option. The current report is the first on the occurrence of human epidermal growth factor receptor 2 amplification in pulmonary adenoid cystic carcinoma. The patient was treated with pyrotinib for 6 months and achieved stable disease.
format Online
Article
Text
id pubmed-8012760
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80127602021-04-02 Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma Tang, Zhongben Lin, Feng Xiao, Jiarong Du, Xiaojun Zhang, Jian Li, Sini Tang, Gongshun Chen, Chen Li, Jian Front Oncol Oncology Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiotherapy and patients benefit less from chemotherapy, but few studies have focused on targeted therapy, and their conclusions are inconsistent. With respect to primary pulmonary adenoid cystic carcinoma, large-scale studies cannot be conducted due to its low incidence, and studies on the targeted therapy of it are very scarce. A few case reports indicate that targeted therapy can be effective however, suggesting that it may be a good option. The current report is the first on the occurrence of human epidermal growth factor receptor 2 amplification in pulmonary adenoid cystic carcinoma. The patient was treated with pyrotinib for 6 months and achieved stable disease. Frontiers Media S.A. 2021-03-18 /pmc/articles/PMC8012760/ /pubmed/33816237 http://dx.doi.org/10.3389/fonc.2021.605658 Text en Copyright © 2021 Tang, Lin, Xiao, Du, Zhang, Li, Tang, Chen and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tang, Zhongben
Lin, Feng
Xiao, Jiarong
Du, Xiaojun
Zhang, Jian
Li, Sini
Tang, Gongshun
Chen, Chen
Li, Jian
Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title_full Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title_fullStr Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title_full_unstemmed Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title_short Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
title_sort case report: efficacy of pyrotinib in erbb2 amplification pulmonary adenoid cystic carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012760/
https://www.ncbi.nlm.nih.gov/pubmed/33816237
http://dx.doi.org/10.3389/fonc.2021.605658
work_keys_str_mv AT tangzhongben casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT linfeng casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT xiaojiarong casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT duxiaojun casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT zhangjian casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT lisini casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT tanggongshun casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT chenchen casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma
AT lijian casereportefficacyofpyrotinibinerbb2amplificationpulmonaryadenoidcysticcarcinoma